# DESCRIPTION

## TECHNICAL FIELD

- relate invention to TF-PAR2 signaling pathway

## BACKGROUND ART

- discuss wound healing and cardiac dysfunction
- summarize prior art on TF and FVIIa inhibitors

## DISCLOSURE OF INVENTION

- introduce heart failure treatment
- describe TF-PAR2 signaling pathway
- motivate PAR2 as therapeutic target
- summarize TF-PAR2 signaling in myeloid cells
- describe TF-PAR2 inhibitors
- introduce NAPc2 as TF-PAR2 inhibitor
- describe NAPc2 variants and modifications
- outline dosing and administration of TF-PAR2 inhibitors
- describe pharmaceutical compositions
- summarize method for treating heart failure

### Conclusions

- summarize invention's significance

## DESCRIPTION OF EMBODIMENTS

- introduce surprising discovery of myeloid cell TF-PAR2 signaling as a crucial driver for TGF-β1 activation and target for treatment or prevention

### EXAMPLES

- investigate molecular pathophysiology of failing myocardium in IHF using proteomics and phospho-proteomic profiling
- evaluate contributions of MAPK pathway to IHF by blocking ERK1/2 activator MEK with trametinib in preclinical mouse model
- demonstrate role of myeloid cell PAR2 signaling in promoting TGF-β1 activation and cardiac remodeling post MI
- show that TF-PAR2 signaling in infiltrating myeloid cells is responsible for ischemia-associated hyper-activation of MAPK pathway and TGF
- investigate role of TF cytoplasmic domain signaling in pro-fibrotic TGF-β1 activation in permanent MI
- demonstrate that myeloid cell TF cytoplasmic domain phosphorylation is linked to NOX2/ERK-dependent TGF-β1 activation
- evaluate feasibility of pharmacological targeting of TF signaling in cardiac remodeling after MI using NAPc2

## DETAILED DESCRIPTION OF THE FIGURES

- describe experimental design of mouse model
- analyze protein expression in heart biopsies
- show inhibition of ERK1/2 activation in mouse model
- investigate PAR-2 mediated ROS signaling in monocytes
- analyze TF cytoplasmic tail deletion in mouse model
- show myeloid cell TF cytoplasmic domain phosphorylation
- analyze pharmacological targeting of TF-FVIIa
- show protein expression analysis of various signaling pathways
- analyze deficiency of coagulation factor VII and integrinβ1 in myeloid cells

## Material and Methods:

- enroll patients in MICAT study
- isolate monocytes from peripheral blood
- prepare human heart samples for analysis
- perform proteomic profiling of human hearts
- analyze phosphopeptides
- describe animal models and treatments
- outline bone marrow transplantation procedure
- describe echocardiography
- describe flow cytometry analysis
- describe DHE-HPLC
- describe monocytes isolation and in vitro culture
- describe confocal microscopy, western blotting, quantitative RT-PCR, and statistical analysis

### Non-Patent Literature

- list non-patent literature references
- describe fibrin structure and wound healing
- discuss composition of coronary thrombus in acute myocardial infarction
- summarize biological basis for cardiac repair after myocardial infarction
- review cardioimmunology and immune system in cardiac homeostasis and disease
- describe regulation of monocyte procoagulant activity in acute myocardial infarction
- discuss various aspects of blood coagulation, thrombosis, and cardiac disease

